Pharming Group announced positive topline data from its Phase II trial of leniolisib, a drug targeting immune dysregulation in genetic primary immunodeficiencies (PIDs) beyond APDS. The trial showed leniolisib was well-tolerated and led to significant improvements in spleen size, lymph node reduction, lung function, and liver stiffness in patients. All participants who completed the study opted to continue treatment in a long-term extension. These results support Pharming's strategy to expand leniolisib's use across various PIDs and anticipate further data from a related Phase II trial in common variable immunodeficiency (CVID) soon.
Pharming's positive Phase II data for leniolisib in genetic PIDs offers context alongside Pluang's health sector market snapshot. As of Oct 14, 2026 09:11 WIB, 32 of 128 priced US health stocks rose while 96 fell. Notable movers include SELLAS Life Sciences Group Inc. with a 5.36% gain and Johnson & Johnson down 5.54%.
Shield appointed Michelle Clark, former HSBC surveillance leader, as Global Communications Surveillance Expert to enhance its AI-driven product strategy. Clark's 20+ years in global banking and expertise in regulatory compliance and AI innovation wil...
Phonak has introduced Roger On Sphere™, the world's first remote microphone using AI to separate speech from background noise in real time. This device enhances communication for people with hearing loss in noisy environments like restaurants and mee...
Southern Company, operating through Georgia Power, Alabama Power, and Mississippi Power, reported a data breach compromising customer personal information including names, addresses, Social Security numbers, and financial details. This breach raises ...
Intel's stock price has almost tripled in 2026, showing strong recent performance. However, a $10,000 investment in Intel made in 2016 would still be worth less than if it had been invested in the S&P 500 index. This highlights that despite recent ga...
The Avantis U.S. Mid Cap Value ETF (AVMV) is rated a Buy at $78, focusing on profitable mid-cap stocks with attractive valuations. The fund uses a systematic approach emphasizing value, size, and profitability, with a low fee of 0.20% and a price-to-...
